{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T21:06:03Z","timestamp":1791752763036,"version":"4.3.4"},"reference-count":55,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There is no single category in the fourth edition (2008) of the World Health Organization (WHO) classification of myeloid neoplasms that encompasses all of the diseases referred to by some authors as the myeloproliferative neoplasm (MPN) \u201cvariants.\u201d Instead, they are considered as distinct entities and are distributed among various subgroups of myeloid neoplasms in the classification scheme. These relatively uncommon neoplasms do not meet the criteria for any so-called \u201cclassical\u201d MPN (chronic myelogenous leukemia, polycythemia vera, primary myelofibrosis, or essential thrombocythemia) and, although some exhibit myelodysplasia, none meets the criteria for any myelodysplastic syndrome (MDS). They are a diverse group of neoplasms ranging from fairly well-characterized disorders such as chronic myelomonocytic leukemia to rare and thus poorly characterized disorders such as chronic neutrophilic leukemia. Recently, however, there has been a surge of information regarding the genetic infrastructure of neoplastic cells in the MPN variants, allowing some to be molecularly defined. Nevertheless, in most cases, correlation of clinical, genetic, and morphologic findings is required for diagnosis and classification. The fourth edition of the WHO classification provides a framework to incorporate those neoplasms in which a genetic abnormality is a major defining criterion of the disease, such as those associated with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1, as well as for those in which no specific genetic defect has yet been discovered and which remain clinically and pathologically defined. An understanding of the clinical, morphologic, and genetic features of the MPN variants will facilitate their diagnosis.<\/jats:p>","DOI":"10.1182\/asheducation-2011.1.250","type":"journal-article","created":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T20:33:13Z","timestamp":1323289993000},"page":"250-256","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":40,"title":["World Health Organization Classification, Evaluation, and Genetics of the Myeloproliferative Neoplasm Variants"],"prefix":"10.1182","volume":"2011","author":[{"given":"James","family":"Vardiman","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hyjek","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111716220244100_B1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.4065\/81.4.553","article-title":"Atypical myeloproliferative disorders: diagnosis and management","volume":"81","author":"Tefferi","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"2019111716220244100_B2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.transci.2011.01.017","article-title":"Atypical myeloproliferative disorders in adults","volume":"44","author":"Zach\u00e9e","year":"2011","journal-title":"Transfus Apher Sci"},{"key":"2019111716220244100_B3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3322\/caac.20009","article-title":"Advances in understanding and management of myeloproliferative neoplasms","volume":"59","author":"Vannucchi","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"2019111716220244100_B4","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrclinonc.2009.149","article-title":"Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics","volume":"6","author":"Tefferi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"2019111716220244100_B5","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue","author":"Swerdlow","year":"2008"},{"key":"2019111716220244100_B6","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"2019111716220244100_B7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1751-553X.2010.01251.x","article-title":"Diagnosing myelodysplastic\/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders","volume":"32","author":"Hall","year":"2010","journal-title":"Int J Lab Hematol"},{"key":"2019111716220244100_B8","first-page":"18","article-title":"Introduction and overview of the classification of the myeloid neoplasms","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue","author":"Vardiman","year":"2008"},{"key":"2019111716220244100_B9","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1309\/AJCPFNF5MN1GDWKU","article-title":"The specificity of immunophenotypic alterations in blasts in nonacute myeloid disorders","volume":"134","author":"Harrington","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"2019111716220244100_B10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1309\/HRJ1XKTD77J1UTFM","article-title":"Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis","volume":"124","author":"Xu","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"2019111716220244100_B11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","article-title":"Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation","volume":"77","author":"Golub","year":"1994","journal-title":"Cell"},{"key":"2019111716220244100_B12","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111716220244100_B13","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3324\/haematol.2009.021675","article-title":"Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1","volume":"95","author":"Bain","year":"2010","journal-title":"Haematologica"},{"key":"2019111716220244100_B14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/MOH.0b013e3283366c70","article-title":"Eosinophilic myeloid disorders: new classification and novel therapeutic strategies","volume":"17","author":"Gotlib","year":"2010","journal-title":"Curr Opin Hematol"},{"key":"2019111716220244100_B15","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.leu.2404662","article-title":"Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma","volume":"21","author":"Metzgeroth","year":"2007","journal-title":"Leukemia"},{"key":"2019111716220244100_B16","first-page":"38","article-title":"Chronic neutrophilic leukaemia","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue","author":"Bain","year":"2008"},{"key":"2019111716220244100_B17","doi-asserted-by":"crossref","first-page":"7719","DOI":"10.1074\/jbc.M807489200","article-title":"FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem\/progenitor cells","volume":"284","author":"Fukushima","year":"2009","journal-title":"J Biol Chem"},{"key":"2019111716220244100_B18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1046\/j.1440-1711.2003.01199.x","article-title":"Fibroblast growth factor receptor-1 interacts with the T-cell receptor signalling pathway","volume":"81","author":"Byrd","year":"2003","journal-title":"Immunol Cell Biol"},{"key":"2019111716220244100_B19","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000305552","article-title":"Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review","volume":"77","author":"Horny","year":"2010","journal-title":"Pathobiology"},{"key":"2019111716220244100_B20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.iac.2006.05.008","article-title":"Flow cytometric analysis of normal and neoplastic mast cells: role in diagnosis and follow-up of mast cell disease","volume":"26","author":"Escribano","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"2019111716220244100_B21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/modpathol.2010.224","article-title":"Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis","volume":"24","author":"Sotlar","year":"2011","journal-title":"Mod Pathol"},{"key":"2019111716220244100_B22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ajh.21982","article-title":"Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management","volume":"86","author":"Pardanani","year":"2011","journal-title":"Am J Hematol"},{"key":"2019111716220244100_B23","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2009.37","article-title":"Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"2019111716220244100_B24","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2353\/jmoldx.2006.060022","article-title":"Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology","volume":"8","author":"Akin","year":"2006","journal-title":"J Mol Diagn"},{"key":"2019111716220244100_B25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","article-title":"Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay","volume":"13","author":"Kristensen","year":"2011","journal-title":"J Mol Diagn"},{"key":"2019111716220244100_B26","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.beha.2005.07.012","article-title":"Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined","volume":"19","author":"Elliott","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"2019111716220244100_B27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-1-61779-074-4_7","article-title":"Cytogenetics of myeloproliferative neoplasms","volume":"730","author":"Campbell","year":"2011","journal-title":"Methods Mol Biol"},{"key":"2019111716220244100_B28","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.molmed.2005.10.003","article-title":"A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects","volume":"11","author":"James","year":"2005","journal-title":"Trends Mol Med"},{"key":"2019111716220244100_B29","doi-asserted-by":"crossref","first-page":"10349","DOI":"10.1158\/0008-5472.CAN-08-2754","article-title":"250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies","volume":"68","author":"Dunbar","year":"2008","journal-title":"Cancer Res"},{"key":"2019111716220244100_B30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2011.08631.x","article-title":"Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia","volume":"153","author":"Bacher","year":"2011","journal-title":"Br J Haematol"},{"key":"2019111716220244100_B31","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.3324\/haematol.2010.021808","article-title":"Transcription factor mutations in myelodysplastic\/myeloproliferative neoplasms","volume":"95","author":"Ernst","year":"2010","journal-title":"Haematologica"},{"key":"2019111716220244100_B32","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/leu.2008.162","article-title":"Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia","volume":"22","author":"Emanuel","year":"2008","journal-title":"Leukemia"},{"key":"2019111716220244100_B33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3324\/haematol.2009.016865","article-title":"Molecular basis of juvenile myelomonocytic leukemia","volume":"95","author":"de Vries","year":"2010","journal-title":"Haematologica"},{"key":"2019111716220244100_B34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2141.2010.08196.x","article-title":"Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations","volume":"150","author":"Sugimoto","year":"2010","journal-title":"Br J Haematol"},{"key":"2019111716220244100_B35","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/1471-2407-8-299","article-title":"Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes","volume":"8","author":"Gelsi-Boyer","year":"2008","journal-title":"BMC Cancer"},{"key":"2019111716220244100_B36","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-09-2112","article-title":"RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant","volume":"16","author":"Ricci","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2019111716220244100_B37","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.3324\/haematol.2009.014001","article-title":"Molecular basis of myelodysplastic\/myeloproliferative neoplasms","volume":"94","author":"Reiter","year":"2009","journal-title":"Haematologica"},{"key":"2019111716220244100_B38","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2141.2010.08393.x","article-title":"Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia","volume":"151","author":"P\u00e9rez","year":"2010","journal-title":"Br J Haematol"},{"key":"2019111716220244100_B39","first-page":"80","article-title":"Atypical chronic myeloid leukaemia, BCR-ABL1 negative","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue","author":"Vardiman","year":"2008"},{"key":"2019111716220244100_B40","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/leu.2008.119","article-title":"The myelodysplastic\/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features","volume":"22","author":"Orazi","year":"2008","journal-title":"Leukemia"},{"key":"2019111716220244100_B41","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.leukres.2008.04.024","article-title":"Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm","volume":"32","author":"Fend","year":"2008","journal-title":"Leuk Res"},{"key":"2019111716220244100_B42","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"key":"2019111716220244100_B43","first-page":"51","article-title":"Chronic eosinophilic leukemia, not otherwise specified","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue","author":"Bain","year":"2008"},{"key":"2019111716220244100_B44","first-page":"76","article-title":"Chronic myelomonocytic leukaemia","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue","author":"Orazi","year":"2008"},{"key":"2019111716220244100_B45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-007-0403-6","article-title":"The diagnosis of BCR\/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers","volume":"87","author":"Haferlach","year":"2008","journal-title":"Ann Hematol"},{"key":"2019111716220244100_B46","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0165-4608(99)00256-3","article-title":"Cytogenetic studies in patients with mastocytosis","volume":"120","author":"Swolin","year":"2000","journal-title":"Cancer Genet Cytogenet"},{"key":"2019111716220244100_B47","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/leu.2008.218","article-title":"Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs)","volume":"22","author":"Reilly","year":"2008","journal-title":"Leukemia"},{"key":"2019111716220244100_B48","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"key":"2019111716220244100_B49","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2141.1999.01537.x","article-title":"Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder\/myelodysplastic syndrome with an aggressive clinical course","volume":"106","author":"McClure","year":"1999","journal-title":"Br J Haematol"},{"issue":"8","key":"2019111716220244100_B50","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/leu.2009.48","article-title":"RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation","volume":"23","author":"Kuo","year":"2009","journal-title":"Leukemia"},{"key":"2019111716220244100_B51","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","article-title":"Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1","volume":"28","author":"Kohlmann","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111716220244100_B52","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1182\/blood-2010-03-274704","article-title":"Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value","volume":"116","author":"Smith","year":"2010","journal-title":"Blood"},{"key":"2019111716220244100_B53","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/leu.2011.10","article-title":"Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"key":"2019111716220244100_B54","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/leu.2010.52","article-title":"Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS\/myeloproliferative neoplasms","volume":"24","author":"Kosmider","year":"2010","journal-title":"Leukemia"},{"key":"2019111716220244100_B55","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms","volume":"113","author":"Grand","year":"2009","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/250\/1495129\/bep00111000250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/250\/1495129\/bep00111000250.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T13:24:08Z","timestamp":1713187448000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2011\/1\/250\/96452\/World-Health-Organization-Classification"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,10]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2011.1.250","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,10]]}}}